drugset
drugset / Trial / NCT01274195

Hematopoietic Stem Cell Transplantation With Targeted Busulfan and Fludarabine in Pediatric AML

NCT01274195 ↗

Phase 2 Unknown 27 enrolled Seoul National University Hospital
NaSingle-groupOpen-labelTreatment

Summary

In this study we plan to improve the outcome of hematopoietic stem cell transplantation by using optimal busulfan dose through pharmacokinetic study.

Timeline

Start
2011-01
Primary completion
2013-12
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Busulfan Small molecule 80 mg/m2 Intravenous
Subject Busulfan Small molecule 120 mg/m2 Intravenous

Indications

disease related to hematopoietic stem cell transplant